Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24729566 | 1.00 | PIK3CD (0.50) | PIK3CDDPP4DPP8DPP9LMNA | |
| SCHEMBL29302247 | 1.00 | PIK3CD (0.50) | PIK3CDDPP4DPP8DPP9LMNA | |
| SCHEMBL19131027 | 1.00 | PIK3CD (0.50) | PIK3CDDPP4DPP8DPP9LMNA | |
| SCHEMBL15429769 | 1.00 | PIK3CD (0.50) | PIK3CDDPP4DPP8DPP9LMNA | |
| SCHEMBL888602 | 1.00 | PIK3CD (0.50) | PIK3CDDPP4DPP8DPP9LMNA | |
| SCHEMBL21023383 | 0.79 | PIK3CD (0.44) | PIK3CD | |
| SCHEMBL26959605 | 0.78 | PIK3CD (0.39) | PIK3CDLMNACYP2C9 | |
| SCHEMBL26448946 | 0.78 | PIK3CD (0.39) | PIK3CDLMNACYP2C9 | |
| SCHEMBL23748937 | 0.78 | PIK3CD (0.39) | PIK3CDLMNACYP2C9 | |
| SCHEMBL29296256 | 0.75 | PIK3CD (0.37) | PIK3CDDPP4LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291026-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2020-09-17 | — | — | US | disclosed |
| US-10688100-B2 | Macrocylic compounds as ROS1 kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10647730-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190076437-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-03-14 | — | — | US | disclosed |
| US-20190076436-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-03-14 | — | — | US | disclosed |
| US-20190031684-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-01-31 | — | — | US | disclosed |
| US-9902741-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902741-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9840519-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840519-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170114059-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170112842-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114059-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170107232-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-20 | — | — | US | disclosed |
| US-20170107232-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-20 | — | — | US | disclosed |
| US-9493476-B2 | Macrocyclic compounds as trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150336970-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2015-11-26 | — | — | US | disclosed |
| US-8933084-B2 | Macrocyclic compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130203776-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-08-08 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203776-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | PIK3CD 624/4885DPP4 1958/4885DPP8 2016/4885 |
| US-20200291026-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | PIK3CD 624/4885DPP4 1958/4885DPP8 2016/4885 |
| US-20190031684-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | PIK3CD 623/4885DPP4 2338/4885DPP8 2363/4885 |
| US-20150336970-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | PIK3CD 627/4885DPP4 1891/4885DPP8 1959/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | PIK3CD 999/4885DPP4 3298/4885DPP8 2918/4885 |
| US-10688100-B2 | Macrocylic compounds as ROS1 kinase inhibitors | ROS1, MAP3K1, MAP3K11 | PIK3CD 503/4885DPP4 4006/4885DPP8 3937/4885 |
| US-10647730-B2 | Macrocyclic compounds as TRK kinase inhibitors | MAP3K20, MAP3K1, MAP3K3 | PIK3CD 623/4885DPP4 2338/4885DPP8 2363/4885 |
| US-20170107232-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | PIK3CD 595/4885DPP4 2179/4885DPP8 2161/4885 |
| US-20190076436-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ROS1, MAP3K1, MAP3K19 | PIK3CD 368/4885DPP4 4257/4885DPP8 3959/4885 |
| US-20170114059-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | PIK3CD 624/4885DPP4 1958/4885DPP8 2016/4885 |
| US-20190076437-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ROS1, MAP3K1, MAP3K19 | PIK3CD 368/4885DPP4 4257/4885DPP8 3959/4885 |
| US-20170112842-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | PIK3CD 624/4885DPP4 1958/4885DPP8 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.